Home | Current Issue | Past Issues | Search | CollectionsRSS | PDA Services | FAQ | SHCIM Online | Chinese Updated Thursday, April 24, 2014
 Services
Submit a manuscript
Subscribe
Individuals
Institutions
Response
Send response
Read responses
Reprint
Advance online publication
Sign up for e-alert
JCIM job opportunities
Contact JCIM
 Information For
Readers
Authors
Reviewers
Advertisers
 About JCIM
Journal description
Editorial policy
Privacy policy
Copy right
Editorial staff
 Language Polishing
Journal of Chinese Integrative Medicine: 2008; 6(1): 25-31
DOI: 10.3736/jcim20080106
A randomized, controlled, double-blind trial of Huannao Yicong capsule in senile patients with mild cognitive impairment
1. Hao LI (Department of Geriatrics, China Academy of Chinese Medical Sciences, Beijing 100091, China E-mail: xyhplihao@vip.sohu.com)
2. Ming-jiang YAO (Department of Geriatrics, China Academy of Chinese Medical Sciences, Beijing 100091, China )
3. Wen-ming ZHAO (Department of Geriatrics, China Academy of Chinese Medical Sciences, Beijing 100091, China )
4. Jie GUAN (Department of Geriatrics, China Academy of Chinese Medical Sciences, Beijing 100091, China )
5. Lin-lin CAI (Department of Geriatrics, China Academy of Chinese Medical Sciences, Beijing 100091, China )
6. Ling CUI (Department of Geriatrics, China Academy of Chinese Medical Sciences, Beijing 100091, China )

Objective:To observe the effect and explore the mechanism of Huannao Yicong capsule in treating senile patients with mild cognitive impairment (MCI).

Methods:The investigational drugs were packed by blind method. A randomized, double-blind and controlled trial was conducted on ninety senile patients with MCI. Other forty-five senile healthy persons were recruited to the healthy control group. The ninety senile patients were randomly divided into the Huannao Yicong capsule-treated group (45 patients administered with three Huannao Yicong capsules and two aniracetam capsule analogues) and aniracetam-treated group (45 patients treated with two aniracetam capsules and three Huannao Yicong capsule analogues). Patients in the two groups were treated three times daily for 16 weeks. Memory, traditional Chinese medicine syndrome, cerebral blood flow, free radicals and inflammatory mediators, such as superoxide dismutase (SOD), malondialdehyde (MDA), acetylcholinesterase (AchE), interleukin-1α (IL-1α) and interleukin-6 (IL-6) were determined before and after the treatment. Blood lipids, including triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), apolipoprotein A-1 (ApoA-1) and apolipoprotein B-100 (ApoB-100), were detected before and after the treatment. The safety indexes, such as routine tests of blood and urine, hepatic and renal function tests and electrocardiogram (ECG) were taken before and after the treatment.

Results:Index score of clinical memory scale in senile healthy people was significantly higher than that in MCI patients before treatment (P<0.01), and the content of AchE, IL-1α and IL-6 was obviously lower (P<0.01, P<0.05), the activity of SOD was higher (P<0.05). No significant difference was found in direction memory of clinical memory scale between the two treatment groups. Other index scores of clinical memory scale and traditional Chinese medicine syndrome in patients of Huannao Yicong capsule-treated group were significantly improved as compared with those of the aniracetam-treated group (P<0.05, P<0.01). The blood flow parameters of anterior cerebral artery, posterior cerebral artery and resistant index in patients of Huannao Yicong capsule-treated group were increased significantly (P<0.01, P<0.05). Huannao Yicong capsule could significantly increase the activity of serum SOD and decrease the content of AchE, IL-1α and IL-6 (P<0.01, P<0.05), better than aniracetam. Furthermore, Huannao Yicong capsule could significantly improve the blood lipid, such as the level of TG, LDL-C, HDL-C, ApoA-1 and ApoB-100 (P<0.01, P<0.05), and better than aniracetam (P<0.01, P0.05). No significant changes were found after treatment in safety indexes, such as routine tests of blood and urine, hepatic and renal function tests and ECG.

Conclusion: Huannao Yicong capsule has better therapeutic effect than aniracetam capsule in treating senile mild cognitive impairment.

Welcome to JCIM! You are the number 6325 reader of this article!
Download Article:
[Full Text]      [PDF]      [Chinese]      [Previous]      [Next]      [This Issue]
Please cite this article as:
Li H, Yao MJ, Zhao WM, Guan J, Cai LL, Cui L. A randomized, controlled, double-blind trial of Huannao Yicong capsule in senile patients with mild cognitive impairment. J Chin Integr Med / Zhong Xi Yi Jie He Xue Bao. 2008; 6(1): 25-31.
References:
1Wen HB, Zhou HB. Changes of cerebral blood flow in patients with mild cognitive impairment[J].Zhongguo Lin Chuang Kang Fu, 2005, 9(37): 6-7. Chinese with abstract in English.
2American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-Ⅳ)[M]. 4th ed. Washington: American Psychiatric Association, 1994. 143-147.  .
3Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome[J].Arch Neurol, 1999, 56(3): 303-308.  .
4Reisberg B, Ferris SH, de Leon MJ, et al. The Global Deterioration Scale for the assessment of primary degenerative dementia[J].Am J Psychiatry, 1982, 139(9): 1136-1139.  .
5Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia[J].Br J Psychiatry, 1982, 140: 566-572.  .
6Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician[J].J Psychiatr Res, 1975, 12(3): 189-198.  .
7Clinical Memory Scale Editing Cooperation Group. Handbook of clinical memory scale[M]. Beijing: Institute of Psychology, Chinese Academy of Sciences, 1996. 27-35. Chinese.
8Zheng XY. The clinical research principle of new traditional Chinese medicine[M]. Beijing: China Medical-Pharmaceutical Science and Technology Publishing House, 2002. 92-96. Chinese.
9Panza F, Capurso C, D'Introno A, et al. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline[J].Neurology, 2007, 68(12): 964-965.  .
10Gao P, Qin SS, Liu YH, et al. Study on the correlation between cognitive functions and regional blood flow in Alzheimer disease and mild cognitive impairment[J].Zhongguo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi, 2006, 13(4): 205-208. Chinese with abstract in English.
11Fu H, Wang XM, Liu GX, et al. Study on relationship between mild cognitive impairment and oxygen free radical metabolism, acetylcholinesterase[J].Zhongguo Lao Nian Xue Za zhi, 2004, 24(1): 17-18. Chinese with abstract in English.
12Weisman D, Hakimian E, Ho GJ. Interleukins, inflammation, and mechanisms of Alzheimer's disease[J].Vitam Horm, 2006, 74: 505-530.  .
13Ma LH, Dong WQ, Lin GZ. Metabolism of serum lipids in elder patients with mild cognitive impairment[J].Xin Nao Xue Guan Bing Fang Zhi, 2005, 5(6): 28-29. Chinese.

 Home | Current Issue | Past Issues | Search | CollectionsRSS | PDA Services | FAQ | SHCIM Online | Chinese
Copyright © 2003-2012 by JCIM Press. All rights reserved. ISSN 1672-1977